Payment overview · 2025
General Payments
$1,373.68
61 reported records · 16 companies
Healthcare provider profile · identity verified
Jairo Rodriguez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · SAN BENITO, TX · NPI 1689625741
Verified facts
What the public records show
CMS Open Payments records show Jairo Rodriguez, M.D. received $1,373.68 in general payments during 2025 across 61 reported records.
Insmed, Inc. accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Uptravi.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Opsumit by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UPTRAVI as an associated drug or biological on 21562 records involving 9341 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Uptravi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Verquvo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insmed, Inc. | Unresolved — no canonical attribution shown | $355.45 | 25.9% | 30 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $198.80 | 14.5% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $152.39 | 11.1% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $112.05 | 8.2% | 1 | 2025 |
| Ethicon Inc. | Unresolved — no canonical attribution shown | $93.21 | 6.8% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $79.37 | 5.8% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $77.26 | 5.6% | 3 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $75.96 | 5.5% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.70 | 2.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $32.65 | 2.4% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $32.38 | 2.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.54 | 2.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.38 | 2.3% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $28.68 | 2.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.62 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.24 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,373.68 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $355.45 | 30 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $198.80 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $152.39 | 2 | 2025 |
Source payment records
|
|||||
| TYVASO Normalized: tyvaso |
Drug | United Therapeutics Corporation | $112.05 | 1 | 2025 |
Source payment records
|
|||||
| Monarch Platform Normalized: monarch platform |
Device | Ethicon Inc. | $93.21 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $79.37 | 3 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $77.26 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $77.26 | 3 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $75.96 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.70 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $32.38 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.54 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $28.68 | 1 | 2025 |
Source payment records
|
|||||
| ILLUMISITE Normalized: illumisite |
Device | Medtronic, Inc. | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| Respiratory Normalized: respiratory |
Device | Philips North America LLC | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| Home PI Undivided Normalized: home pi undivided |
Device | Philips North America LLC | $16.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| UPTRAVI uptravi |
2025 | Uptravi | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | UPTRAVI open payments reported associated product |
CMS Open Payments — General Payments 21562 supporting records · 9341 recipient NPIs · example record 1174163984 |
Uptravi · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
84 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 979 | 412 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 580 | 228 |
| Montelukast Sodium | Montelukast Sodium | 573 | 230 |
| Breo Ellipta | Fluticasone/Vilanterol | 379 | 146 |
| Ofev | Nintedanib Esylate | 257 | 43 |
| Prednisone | Prednisone | 245 | 176 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 209 | 98 |
| Furosemide | Furosemide | 195 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 179 | 50 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 168 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 154 | 37 |
| Levofloxacin | Levofloxacin | 144 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 136 | 34 |
| Azithromycin | Azithromycin | 129 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 26 |
| Levetiracetam | Levetiracetam | 104 | 25 |
| Metformin Hcl | Metformin Hcl | 103 | 24 |
| Gabapentin | Gabapentin | 101 | 33 |
| Famotidine | Famotidine | 98 | 29 |
| Lisinopril | Lisinopril | 98 | 22 |
| Eliquis | Apixaban | 93 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 84 | 33 |
| Potassium Chloride | Potassium Chloride | 83 | 24 |
| Sertraline Hcl | Sertraline Hcl | 83 | 19 |
| Theophylline Er | Theophylline Anhydrous | 82 | 25 |
| Lactulose | Lactulose | 80 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 42 |
| Buspirone Hcl | Buspirone Hcl | 77 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 76 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 22 |
| Trazodone Hcl | Trazodone Hcl | 74 | 19 |
| Entresto | Sacubitril/Valsartan | 72 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 72 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 69 | 18 |
| Mirtazapine | Mirtazapine | 66 | 12 |
| Memantine Hcl | Memantine Hcl | 64 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 61 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 51 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 24 |
| Gemtesa | Vibegron | 54 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 54 | 11 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 52 | 23 |
| Spiriva Respimat | Tiotropium Bromide | 51 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 14 |
| Losartan Potassium | Losartan Potassium | 49 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 45 | 18 |
| Carvedilol | Carvedilol | 44 | 17 |
| Humulin R | Insulin Regular, Human | 44 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 42 | 18 |
| Albuterol Sulfate | Albuterol Sulfate | 40 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 11 |
| Omeprazole | Omeprazole | 40 | 13 |
| Risperidone | Risperidone | 39 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 37 | 16 |
| Baclofen | Baclofen | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 31 |
| Sucralfate | Sucralfate | 35 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 11 |
| Kerendia | Finerenone | 33 | suppressed |
| Pirfenidone | Pirfenidone | 33 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 32 | 16 |
| Dupixent Pen | Dupilumab | 32 | suppressed |
| Uptravi | Selexipag | 32 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 31 | 13 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 30 | 27 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 27 |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | 13 |
| Alprazolam | Alprazolam | 28 | suppressed |
| Lubiprostone | Lubiprostone | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 25 | 12 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 25 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Opsumit | Macitentan | 23 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Paliperidone Er | Paliperidone | 21 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | 12 |
| Olanzapine | Olanzapine | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Meropenem | Meropenem | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Verquvo | Vericiguat | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Valproic Acid | Valproic Acid | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Water | Water For Irrigation,sterile | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Glucagon Emergency Kit | Glucagon | 12 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Bosentan | Bosentan | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Drizalma Sprinkle | Duloxetine Hcl | 11 | suppressed |
| Esbriet | Pirfenidone | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Roflumilast | Roflumilast | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,373.68 · 61 records | Insmed, Inc. | ARISTADA, Arikayce, BREZTRI, Brinsupri, CAPLYTA, DUPIXENT, Home PI Undivided, ILLUMISITE, INSPIRE, LYBALVI, Monarch Platform, Ohtuvayre, Respiratory, SMARTVEST, TYVASO, UPTRAVI, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Uptravi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error